Sachs Immuno-Oncology BD&L and Investment Forum and 2018 BIO International Convention

AUSTIN, Texas & HAMILTON, Ontario – Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple types of cancers, today announced that it will present a company overview at the 4th Annual Immuno-Oncology Business Development & Licensing and Investment Forum (IOBDLI), in Chicago on June 1, and attend the 2018 BIO International Convention in Boston on June 4-5.

At the IOBDLI Forum, Triumvira Scientific Founder and Acting Chief Scientific Officer, Dr. Jonathan Bramson, will provide an overview of the company’s T Cell-Antigen Coupler (TAC) technology, as well as updates on Triumvira’s lead drug, CD19-TAC01, which is targeted to enter clinical development in H1 2019 for the treatment of patients with CD19 positive B-cell malignancies. Dr. Bramson will be presenting at 3:20 p.m. CT on June 1.

At BIO International, President and Chief Executive Officer, Dr. Paul Lammers will be available for private meetings during the day on June 4-5 to discuss potential collaboration and licensing opportunities for the Company’s novel immuno-oncology platform T Cell-Antigen Coupler (TAC).

About the IOBDLI Forum
The 4th Annual Immuno-Oncology BD&L and Investment Forum, a by-invitation-only event to be held at the Waldorf Astoria Chicago Hotel, is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment.

About the 2018 BIO International Convention
The BIO International Convention, to be held at the Boston Convention and Exhibition Center, is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.

About Triumvira Immunologics
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, with our research facilities in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to partners@triumvira.com

For more information
LaVoieHealthScience
Beth Kurth
Vice President, Investor Relations & Corporate Communications
Phone: +1 617-374-8800, Ext. 106
bkurth@lavoiehealthscience.com

Innovative immuno-therapy company welcomes proven leaders in pharma and therapeutics

AUSTIN, Texas & HAMILTON, Ontario – Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today formally announced the appointments of Sabine Chlosta, MD, PhD, as Chief Medical Officer, and Jon Irvin as Vice President, Finance.

“We are delighted to expand our executive management team with Dr. Chlosta and Mr. Irvin,” said Paul Lammers, MD, MSc., President and CEO of Triumvira Immunologics. “We look forward to leveraging Sabine’s extensive experience in immuno-oncology and clinical trial oversight as we work to develop and commercialize innovative therapies that will empower a patient’s own immune system to tackle serious and life-threatening diseases.”

“In addition, Jon’s finance expertise in the pharmaceutical and technology industries will be a strong asset to Triumvira as we build our company to bring new treatments to patients in need,” Lammers added.

Prior to Triumvira, Sabine Chlosta consulted for Aurora BioPharma, a start-up company developing CAR-T cells in solid tumors and was previously a Senior Medical Director at Merck & Co. where she played a key role in the development of its PD-1 inhibitor Keytruda® in Non-Hodgkin’s lymphoma and oversaw trials in other indications, as well. Earlier in her career, Dr. Chlosta was a medical director at Glycomimetics where she helped launch the company’s first trial in cancer. She began her industry career as a Fellow in Oncology Drug Development at Novartis overseeing clinical pharmacology trials with a small molecule and helped launch their CAR-T lymphoma program with Kymriah®. Dr. Chlosta is a board-certified pediatric hematologist oncologist out of Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College.

“Triumvira is poised for growth and success in T cell therapy, and I am thrilled to be part of the team to take our innovative TAC technology into the clinic,” said Dr. Chlosta.

Jon Irvin was the Chief Financial Officer and Vice President of Finance at Mirna Therapeutics, a publicly traded biotechnology company, before joining Triumvira. He also served in executive financial positions for Voxpath Networks, Inc., a telecommunications and intellectual property company, Reddwerks Corporation, a software company, Esoterix, Inc., a medical laboratory company, Topaz Technologies, a pharmaceutical software company, and BioNumerik Pharmaceuticals, Inc., a pharmaceutical company. Mr. Irvin previously worked with Ernst & Young’s life science practice in Palo Alto, California.

Irvin commented, “It’s exciting to be a part of this growing team as we develop our novel platform to treat patients’ unmet medical needs.”

About Triumvira Immunologics

Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, with our research facilities in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to partners@triumvira.com

For more information
LaVoieHealthScience
Beth Kurth
Vice President, Investor Relations & Corporate Communications
Phone: +1 617 374 8800, Ext. 106
bkurth@lavoiehealthscience.com

AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple cancers, today announced a strategic relationship with the Centre for Commercialisation of Cancer Immunotherapy (C3i), a catalyst for accelerating market access of breakthrough innovations to fight cancer. Under the terms of the agreement, C3i will deliver cell therapy products for Triumvira’s global Phase 1 and 2 clinical trials and has committed to underwrite an investment in the company.

“We are very pleased to be working with C3i for the manufacturing at the Centre of Excellence in Cellular Therapy (CETC) GMP manufacturing facility. It is critical for us to have a supplier with specific expertise in cellular therapies, including cancer immunotherapies,” said Paul Lammers, MD, MSc, President & CEO, Triumvira. “As we work toward our goal of entering clinical development in 2019, we understand the importance of securing sufficient product from a state-of-the-art facility.”

Read Complete Article